» Authors » Akinaru Yamamoto

Akinaru Yamamoto

Explore the profile of Akinaru Yamamoto including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 63
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ishizuya Y, Kawashima A, Horibe Y, Yamamoto A, Tani M, Yoshimura A, et al.
Sci Rep . 2025 Feb; 15(1):4640. PMID: 39920103
We have reported that the FAN score, which consists of the fibrosis-4 (Fib-4) index, albumin-bilirubin (ALBI) score, and neutrophil-lymphocyte ratio (NLR), is a prognostic marker for patients receiving pembrolizumab for...
2.
Yamamichi G, Kato T, Yoshimura A, Tani M, Horibe Y, Liu Y, et al.
Anticancer Res . 2025 Jan; 45(2):639-650. PMID: 39890197
Background/aim: Combination therapy with immune checkpoint inhibitors has become the standard first-line treatment for metastatic renal cell carcinoma (mRCC), leading to changes in second-line treatment options, such as nivolumab or...
3.
Yamamoto A, Kawashima A, Uemura T, Nakano K, Matsushita M, Ishizuya Y, et al.
Int J Cancer . 2024 Dec; 156(7):1439-1456. PMID: 39693209
Animal models of N-butyl-N-(4-hydroxy butyl) nitrosamine (BBN)-induced urothelial carcinoma (UC), particularly bladder cancer (BC), have long been established. However, the rare incidence of BBN-induced upper urinary tract UC (UTUC), which...
4.
Uemura T, Kawashima A, Jingushi K, Motooka D, Saito T, Sassi N, et al.
Cancer Sci . 2024 Nov; 116(2):338-349. PMID: 39566543
Adipose tissue and bacterial flora are involved in metabolism in the human body. However, the relationship between the two remains unclear. Recently, the presence of circulating bacterial DNAs has been...
5.
Oka T, Hatano K, Tani M, Yoshimura A, Horibe Y, Liu Y, et al.
Cancer Diagn Progn . 2024 Nov; 4(6):706-714. PMID: 39502601
Background/aim: There is little evidence regarding the predictive value of prostate-specific antigen (PSA) kinetics in patients with castration-resistant prostate cancer treated with an androgen receptor signaling inhibitor. This study investigated...
6.
Yamamoto A, Kawashima A, Sakai S, Mita M, Sassi N, Inoguchi S, et al.
Biochem Biophys Res Commun . 2024 Sep; 733:150701. PMID: 39326256
The sensitivity of currently available screening tools for urothelial carcinoma (UC) remains unsatisfactory particularly at early stages. Hence, we aimed to establish a novel blood-based screening tool for urothelial carcinoma....
7.
Tani M, Hatano K, Yoshimura A, Horibe Y, Liu Y, Sassi N, et al.
Sci Rep . 2024 Jun; 14(1):13451. PMID: 38862617
Bone-modifying agents (BMA) are extensively used in treating patients with prostate cancer with bone metastases. However, this increases the risk of medication-related osteonecrosis of the jaw (MRONJ). The safety of...
8.
Jingushi K, Kawashima A, Tanikawa S, Saito T, Yamamoto A, Uemura T, et al.
Cancer Sci . 2024 Apr; 115(8):2578-2587. PMID: 38682309
Bacterial flora are present in various parts of the human body, including the intestine, and are thought to be involved in the etiology of various diseases such as multiple sclerosis,...
9.
Uemura T, Kawashima A, Jingushi K, Motooka D, Saito T, Nesrine S, et al.
Heliyon . 2023 Oct; 9(9):e19800. PMID: 37810127
This is the first study to determine the clinical importance of circulating bacterial DNA in patients with renal cell carcinoma (RCC). We performed 16S rRNA metagenomic analysis of serum extracellular...
10.
Yamamoto Y, Kawashima A, Morishima T, Uemura T, Yamamoto A, Yamamichi G, et al.
Adv Radiat Oncol . 2023 Mar; 8(3):101157. PMID: 36896218
Purpose: Radical cystectomy (RC) with neoadjuvant chemotherapy is the most commonly recommended treatment for muscle-invasive bladder cancer (MIBC), yet RC with urinary diversion remains an invasive treatment. Although some patients...